The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma
Abstract
Purpose: This multicenter, phase II clinical study was conducted to evaluate the activity of the combination of pemetrexed and carboplatin in patients with malignant pleural mesothelioma (MPM). Patients and Methods: Chemotherapy-naive patients with measurable disease and adequate organ function, who were not eligible for curative surgery, received pemetrexed 500 mg/m 2 and carboplatin area under the plasma concentration-time curve of 5 mg/mL/min, administered intravenously every 21 days. All patients received folic acid and vitamin B 12 supplementation. Pemetrexed was provided within the Expanded Access Program. Results: A total of 102 patients were enrolled. An objective response was achieved in 19 patients (two complete and 17 partial responses), for a response rate of 18.6% (95% CI, 11.6% to 27.5%). Forty-eight patients (47.0%; 95% CI, 37.1% to 57.2%) had stable disease after treatment. Overall, 67 patients (65.7%) achieved disease control (95% CI, 55.6% to 74.8%). Median time to progression was 6.5 months; median overall survival time was 12.7 months. Compliance to treatment was excellent, with a relative dose-intensity of 97% for pemetrexed and 98% for carboplatin. Toxicity was mild, with grade 3 or 4 neutropenia occurring in 9.7% of total cycles and grade 3 or 4 anemia occurring in 3.5% of total cycles. Nonhematologic toxicity was negligible. Conclusion: Treatment with pemetrexed and carboplatin was active and well tolerated in patients with MPM. Disease control rate, time to disease progression, and overall survival were similar to the results achieved with the standard regimen of pemetrexed and cisplatin, suggesting that the carboplatin combination could be an alternative option for these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
A Survey of Exact Inference for Contingency Tables
Agresti, A. (1992) · Statistical Science · doi:10.1214/ss/1177011454 · Cited by 1,097
Sugarbaker, D. J., Flores, R. M., Jaklitsch, M. T., Richards, W. G., Strauss, G. M., Corson, J. M., DeCamp, M. M., Swanson, S. J., Bueno, R., Lukanich, J. M., et al. (1999) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(99)70469-1 · Cited by 985
The European mesothelioma epidemic
Peto, J., Decarli, A., Vecchia, C. L., Levi, F., & Negri, E. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690105 · Cited by 891
Advances in Malignant Mesothelioma
Robinson, B. W. S., & Lake, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050152 · Cited by 889
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma
Byrne, M. J., & Nowak, A. K. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh059 · Cited by 645
van Meerbeeck, J. P., Gaafar, R., Manegold, C., Van Klaveren, R. J., Van Marck, E. A., Vincent, M., Legrand, C., Bottomley, A., Debruyne, C., & Giaccone, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.20005.14.589 · Cited by 617
A Proposed New International TNM Staging System for Malignant Pleural Mesothelioma
(1995) · Chest · doi:10.1378/chest.108.4.1122 · Cited by 606
Curran, D., Sahmoud, T., Therasse, P., van Meerbeeck, J., Postmus, P. E., & Giaccone, G. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.145 · Cited by 543
Sugarbaker, D. J., Jaklitsch, M. T., Bueno, R., Richards, W. G., Lukanich, J. M., Mentzer, S. J., Colson, Y. L., Linden, P. A., Chang, M. Y., Capalbo, L., et al. (2004) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2004.02.021 · Cited by 395
Scagliotti, G. V., Shin, D.-M., Kindler, H. L., Vasconcelles, M. J., Keppler, U., Manegold, C., Burris, H., Gatzemeier, U., Blatter, J., Symanowski, J. T., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.122 · Cited by 251
A Comparison of Approximate Interval Estimators for the Bernoulli Parameter
Leemis, L. M., & Trivedi, K. S. (1996) · The American Statistician · doi:10.1080/00031305.1996.10473544 · Cited by 217
Berghmans, T., Paesmans, M., Lalami, Y., Louviaux, I., Luce, S., Mascaux, C., Meert, A. P., & Sculier, J. P. (2002) · Lung Cancer · doi:10.1016/s0169-5002(02)00180-0 · Cited by 190
Manegold, C., Symanowski, J., Gatzemeier, U., Reck, M., von Pawel, J., Kortsik, C., Nackaerts, K., Lianes, P., & Vogelzang, N. J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi187 · Cited by 160
Thödtmann, R., Depenbrock, H., Dumez, H., Blatter, J., Johnson, R. D., van Oosterom, A., & Hanauske, A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3009 · Cited by 151
Hughes, A., Calvert, P. M., Azzabi, A., Plummer, R., Johnson, R., Rusthoven, J., Griffin, M., Fishwick, K., Boddy, A. V., Verrill, M. W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.073 · Cited by 147
Pemetrexed in Malignant Pleural Mesothelioma
Hazarika, M., White, R. M., Booth, B. P., Wang, Y.-C., Lee-Ham, D. Y., Liang, C. Y., Rahman, A., Gobburu, J. V. S., Li, N., Sridhara, R., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.982.11.3 · Cited by 108
Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
Teicher, B. A., Chen, V., Shih, C., Menon, K., Forler, P., Phares, & Amsrud, T. (2000) · PubMed · Cited by 100
Chemotherapy options and new advances in malignant pleural mesothelioma
Steele, J. P. C., & Klabatsa, A. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi094 · Cited by 62
External beam radiation therapy for the treatment of pleural mesothelioma
Baldini, E. H. (2004) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/s1547-4127(04)00108-2 · Cited by 46
Pemetrexed and Cisplatin for Malignant Pleural Mesothelioma: A New Standard of Care?
Rusch, V. W. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.043 · Cited by 33
Cited by
Zalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., Monnet, I., Gounant, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01238-6 · Cited by 968
Nanoparticles in cellular drug delivery
Faraji, A. H., & Wipf, P. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.02.043 · Cited by 903
Malignant Pleural Mesothelioma
Tsao, A. S., Wistuba, I., Roth, J. A., & Kindler, H. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8523 · Cited by 481
Kindler, H. L., Ismaila, N., Armato, S. G., Bueno, R., Hesdorffer, M., Jahan, T., Jones, C. M., Miettinen, M., Pass, H., Rimner, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.6394 · Cited by 420
Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies
Ho, G. Y., Woodward, N., & Coward, J. I. G. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.03.014 · Cited by 325
Metadata
- Authors
- Ceresoli, G. L., Zucali, P. A., Favaretto, A. G., Grossi, F., Bidoli, P., Del Conte, G., Ceribelli, A., Bearz, A., Morenghi, E., Cavina, R., Marangolo, M., Parra, H. J. S., & Santoro, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-03-20
- Volume
- 24
- Issue
- 9
- Pages
- 1443-1448
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2148716917
- Cited by
- 296
- References
- 26
- FWCI
- 16.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.